Lestaurtinib Terminated Phase 2 Trials for Plasma Cell Myeloma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00242827Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma